Safety and immunogenicity of inactivated hepatitis A vaccine
in patients with chronic liver disease.
Healive is reportedly the first inactivated hepatitis A vaccine
developed, produced and marketed by a China-based manufacturer.
Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine
. Eur J Clin Microbiol Infect Dis 2001; 20: 185-7.
A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine
. Arch Pediatr Adolesc Med 1996;150:733-9.
Inactivated hepatitis A vaccine (HAVRIX[R], Smithkline Beecham, Inc., Pittsburgh, Pennsylvania) was licensed in 1995, and physicians should consider vaccinating susceptible patients who receive clotting factor.
Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
In February 1995, Havrix[R](8), an inactivated hepatitis A vaccine distributed by SmithKline Beecham Pharmaceuticals (Philadelphia, Pennsylvania) was licensed by the Food and Drug Administration for use in persons aged [greater than or equal to]2 years to prevent hepatitis A virus (HAV) infection.
Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children.
In 1995, highly effective inactivated hepatitis A vaccines
were first licensed in the United States for preexposure prophylaxis against hepatitis A virus (HAV) among persons aged [greater than or equal to] 2 years.
The currently licensed inactivated hepatitis A vaccines
are highly immunogenic and clinically effective in children 2 to 18 years and in adults.